Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
RPL21P21 is a processed pseudogene of the ribosomal protein L21 (RPL21) gene, which encodes a structural protein of the 60S ribosomal subunit[1][3][6][8]. Pseudogenes such as RPL21P21 are non-functional copies or fragments of genes; they do not code for active proteins and are not considered therapeutic targets. RPL21P21 itself does not have a known protein product, biological function, or disease association. In contrast, the functional RPL21 gene is involved in ribosome assembly and protein synthesis and has been linked to certain rare hereditary diseases (e.g., Hypotrichosis simplex), but these roles do not apply to its processed pseudogenes[1][5]. Multiple processed pseudogenes exist for many ribosomal proteins, including RPL21, scattered throughout the human genome, but these pseudogenes generally do not have functional, clinical, or pharmacological significance[1][3][6][8].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on ribosomal protein L21 pseudogene 21 (RPL21P21).